Revolutionising Organ Preservation: Innovative Anti-Necrotic Technology for Enhanced Viability and Equity in Transplantation

UK-based biotech SME LinkGevity is led by a diverse and experienced project team. At the helm is Dr Carina Kern, a pioneering female scientist, who is responsible for developing LinkGevity's unique Anti-Necrotic.

Despite the concerning and growing scarcity of transplant organs, 80% of transplantable organs are ultimately wasted due to damage caused by necrosis during preservation (Roderick P Tas,2021).

Necrosis is unprogrammed cell death, which causes irreversible tissue and organ damage due to a lack of oxygen and nutrients. This problem of cells dying due to necrosis in organs results in wastage of otherwise healthy harvested organs, leaving 19 people to die on waiting lists in Europe every single day (Council of Europe, 2024). In the meantime, 5 new people are added to waiting lists every hour (Council of Europe, 2024).

Waiting for a transplant exacerbates health conditions, impacts quality of life and costs large sums in ongoing alternative treatments such as dialysis.

To date, there is no way to intervene in necrosis. Necrosis is not just a hurdle in organ preservation. More broadly, it has hindered the fields of bioengineering and the treatment of chronic disease.

Based on a novel discovery of how necrosis occurs, LinkGevity have identified, and lab tested a novel compound that can, for the first time, directly block necrosis. We call this an Anti-Necrotic.

Our Anti-Necrotic has been shown to block necrosis by an unprecedented 90% and can be added to the fluids used to preserve organs, to for the very first time, stop necrosis damage. The implications of this discovery are vast, holding promise not just for the field of organ preservation but also beyond in the fields of bioengineering as well as for treatments of chronic disease (e.g. renal disease).